NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received Institutional Review Board (IRB) approval for its landmark Phase 1b/2a proof-of-concept clinical trial protocol of its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI). NervGen is now activ
2023-08-08 8:30 AM EDT
NervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that it has been awarded a grant of up to US$3.18 million from Wings for Life, a not-for-profit spinal cord injury research foundation, under the foundation's Accelerated Translational Program. The funding will...
2023-06-27 8:30 AM EDT
NervGen Pharma to Present at Upcoming Investor Conferences
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management will be presenting at two upcoming investor conferences: Mike Kelly, President & CEO, will present at the Life Science Investors Forum, hosted by OTC Markets Group on...
2023-06-20 4:36 PM EDT
NervGen Pharma Extends the Expiry Date of Certain Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options (the "Options") granted to a consultant of the Company on April 23, 2021 and July 16, 2021, such that the terms of the Options shall be extended from three...
2023-06-02 6:15 PM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company, exercisable at a price of $1.61 per share for a period of five years and that vest equally every three months over a one-year period....
2023-05-23 4:30 PM EDT
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on May 17, 2023. "We appreciate the support demonstrated by our shareholders at this AGM," stated Bill Radvak, NervGen's Chairman. "With our Phase 1 clinical trial successfully...
2023-05-18 7:08 PM EDT
NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291
Vancouver, British Columbia--(Newsfile Corp. - May 15, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the first quarter ended March 31, 2023. Operational highlights outlined below refer to NervGen's proprietary lead drug candidate, NVG-291, which has been demons
2023-05-15 8:30 AM EDT
NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury Association (ASIA) 50th Annual Scientific Meeting being held on April 17-19, 2023. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present the study...
2023-04-13 8:30 AM EDT
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Michael Kelly to the position of President & CEO effective April 10, 2023. Mr. Kelly has also been appointed as a member of NervGen's Board of Directors. "We are very excited to welcome Mike...
2023-04-10 8:41 AM EDT
NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial results for the year ended December 31, 2022 and provided an operational update, including details related to the Company's enhanced cash p
2023-03-30 9:00 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, Canada--(Newsfile Corp. - February 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to existing consultants providing investor relations services exercisable at a price of $1.94 per share...
2023-02-23 6:03 PM EST
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company's proprietary lead compound,
2023-02-14 8:30 AM EST
NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University. NervGen has an...
2022-11-17 8:30 AM EST
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - November 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company exercisable at a price of $1.74 per share for a period of five years and that vest equally every three months over a one-year...
2022-11-15 7:16 PM EST
NervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial results for the third quarter ended September 30, 2022 and provided a
2022-11-14 8:30 AM EST
NervGen Engages Cloutier Consulting to Provide Media Relations Services
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Cloutier Consulting, a Texas based public relations specialty agency, to provide media relations and related services for the Company. Cloutier Consulting was engaged for an initial term of one year....
2022-10-31 12:00 PM EDT
NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the repair of nervous system damage, announced that the U.S. Food and Drug Administration (FDA) has amended the partial clinical hold to permit the inclusion of males and premenopausal females at certain dose levels in
2022-10-25 7:30 AM EDT
NervGen Pharma Presenting at Upcoming Scientific Meetings
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting posters at two upcoming scientific meetings - the 147th American Neurological Association (ANA) annual meeting on October 22-25, 2022, and the 38th Congress of the European Committee for Treatment and Research...
2022-10-20 8:30 AM EDT
NervGen Pharma Awarded up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury
Vancouver, British Columbia--(Newsfile Corp. - October 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the repair of nervous system damage, today announced it has
2022-10-12 8:30 AM EDT
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on September 28, 2022. "We appreciate the support from our shareholders demonstrated at this AGM," stated Bill Radvak, NervGen's Executive Chairman and Interim CEO. "With...
2022-09-29 8:30 AM EDT